Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 7/20 | 0.82 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.70 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.70 |
| ▸ | PRKDC | P78527 | 2/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807074 | 0.90 | PIK3CG (0.74) | PIK3CGPIK3CAPIK3CDPIK3CBPRKDC | |
| SCHEMBL909580 | 0.90 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CDPIK3CBPRKDC | |
| SCHEMBL4412270 | 0.90 | PIK3CG (0.83) | PIK3CGPIK3CAPIK3CDPIK3CBPRKDC | |
| SCHEMBL3194294 | 0.86 | PIK3CA (0.81) | PIK3CGPIK3CAPIK3CDPIK3CBPRKDC | |
| SCHEMBL29561311 | 0.86 | PIK3CA (0.81) | PIK3CGPIK3CAPIK3CDPIK3CBPRKDC | |
| SCHEMBL13752241 | 0.83 | PIK3CA (0.60) | PIK3CGPIK3CAPIK3CDPIK3CBPRKDC | |
| SCHEMBL30531414 | 0.82 | PIK3CA (1.00) | PIK3CGPIK3CAPIK3CDPIK3CBPRKDC | |
| SCHEMBL4413439 | 0.82 | PIK3CA (1.00) | PIK3CGPIK3CAPIK3CDPIK3CBPRKDC | |
| SCHEMBL4807667 | 0.81 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CDPIK3CBPRKDC | |
| SCHEMBL4808745 | 0.81 | PIK3CA (0.80) | PIK3CGPIK3CAPIK3CDPIK3CBPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-12-18 | — | — | US | claimed |
| US-7405211-B2 | Using 2-morpholinyl-4H-pyrido(1,2-a)pyrimidin-4-one; enzyme inhibitors; antithrombotic agents ; restenosis; atherosclerosis; antihistamines; chronic obsessive pulminary disease; autoimmune diseases; anticancer agents; antiinflammatory agents | ASTRAZENECA AB (SE) | 2008-07-29 | — | — | US | claimed |
| US-20050085471-A1 | Therapeutic morpholino-substituted compounds | KINACIA PTY LTD. | 2005-04-21 | — | — | US | claimed |
| US-7572791-B2 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-7572791-B2 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-12-18 | — | — | US | disclosed |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-12-18 | — | — | US | disclosed |
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | DIACOVO THOMAS G | 2008-11-20 | — | — | US | disclosed |
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-08-28 | — | — | US | disclosed |
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-08-28 | — | — | US | disclosed |
| US-7405211-B2 | Using 2-morpholinyl-4H-pyrido(1,2-a)pyrimidin-4-one; enzyme inhibitors; antithrombotic agents ; restenosis; atherosclerosis; antihistamines; chronic obsessive pulminary disease; autoimmune diseases; anticancer agents; antiinflammatory agents | ASTRAZENECA AB (SE) | 2008-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085471-A1 | Therapeutic morpholino-substituted compounds | PIK3CA, PTK2, PDPK1 | PIK3CG 17/4885PIK3CA 1/4885PIK3CD 13/4885 |
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | PIK3CA, PTK2, PDPK1 | PIK3CG 17/4885PIK3CA 1/4885PIK3CD 13/4885 |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | PIK3CA, PTK2, PDPK1 | PIK3CG 17/4885PIK3CA 1/4885PIK3CD 13/4885 |
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | PI4KB, PIK3CA, PI4KA | PIK3CG 5/4885PIK3CA 2/4885PIK3CD 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.